SCHEMBL8876967

SCHEMBL8876967

O=CN1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTAFR P25105 2/20 1.00
HRH1 P35367 12/20 0.71
FNTA P49354 5/20 0.71
FNTB P49356 5/20 0.71
SLC6A15 Q9H2J7 5/20 0.71
MEN1 O00255 1/20 0.67
LMNA P02545 1/20 0.67
ADRB2 P07550 1/20 0.67
CHRM2 P08172 1/20 0.67
CHRM4 P08173 1/20 0.67
ABCB1 P08183 1/20 0.67
HTR1A P08908 1/20 0.67
CHRM5 P08912 1/20 0.67
ADRA2A P08913 1/20 0.67
CHRM1 P11229 1/20 0.67
DRD2 P14416 1/20 0.67
ADRA2B P18089 1/20 0.67
ADRA2C P18825 1/20 0.67
CHRM3 P20309 1/20 0.67
DRD1 P21728 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31305643 1.00 PTAFR (1.00) PTAFRHRH1FNTAFNTBSLC6A15
SCHEMBL4460572 0.87 HRH1 (0.82) PTAFRHRH1FNTAFNTBSLC6A15
SCHEMBL31384618 0.87 HRH1 (0.82) PTAFRHRH1FNTAFNTBSLC6A15
SCHEMBL29626502 0.87 HRH1 (0.82) PTAFRHRH1FNTAFNTBSLC6A15
SCHEMBL20777155 0.86 PTAFR (0.75) PTAFRHRH1FNTAFNTBSLC6A15
SCHEMBL8958672 0.86 PTAFR (0.75) PTAFRHRH1FNTAFNTBSLC6A15
SCHEMBL31414621 0.85 PTAFR (0.74) PTAFRHRH1FNTAFNTBSLC6A15
SCHEMBL3367280 0.84 SLC6A15 (0.82) PTAFRHRH1FNTAFNTBSLC6A15
SCHEMBL23303105 0.83 FNTA (1.00) PTAFRHRH1FNTAFNTBSLC6A15
Sch-37370 SCHEMBL3071641 0.83 PTAFR (1.00) PTAFRHRH1FNTAFNTBSLC6A15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8187630-B2 Extended release oral dosage composition SCHERING-PLOUGH CORPORATION (US) 2012-05-29 US disclosed
US-8187630-B2 Extended release oral dosage composition SCHERING-PLOUGH CORPORATION (US) 2012-05-29 US disclosed
US-20100021542-A1 EXTENDED RELEASE ORAL DOSAGE COMPOSITION SCHERING CORPORATION (US) 2010-01-28 US disclosed
US-20100021542-A1 EXTENDED RELEASE ORAL DOSAGE COMPOSITION SCHERING CORPORATION (US) 2010-01-28 US disclosed
US-20070014855-A1 STABLE DESLORATADINE COMPOSITIONS DR. REDDY'S LABORATORIES, INC. 2007-01-18 US disclosed
US-20070014855-A1 STABLE DESLORATADINE COMPOSITIONS DR. REDDY'S LABORATORIES, INC. 2007-01-18 US disclosed
US-5665726-A ANTIALLERGIC, ANTIINFLAMMATORY AGENTS SCHERING CORPORATION (US) 1997-09-09 US disclosed
EP-0685476-A1 Benzo(5,6)cycloheptapyridines, compositions and methods of use SCHERING CORPORATION (US) 1995-12-06 EP disclosed
US-5438062-A Antiallergens, antiinflammatory agents SCHERING CORPORATION (US) 1995-08-01 US disclosed
EP-0270818-B1 Benzo(5,6)cycloheptapyridines, compositions and method of use SCHERING CORP (US) 1994-12-28 EP disclosed
US-5089496-A Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies SCHERING CORPORATION (US) 1992-02-18 US disclosed
EP-0330673-A1 BENZO 5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE SCHERING CORPORATION (US) 1989-09-06 EP disclosed
US-4826853-A ANTIALLERGENS, ANTIINFLAMMATORY AGENTS SCHERING CORPORATION (US) 1989-05-02 US disclosed
EP-0270818-A1 Benzo(5,6)cycloheptapyridines, compositions and method of use SCHERING CORPORATION (US) 1988-06-15 EP disclosed
WO-1988003138-A1 BENZO[5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE SCHERING CORPORATION (US) 1988-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070014855-A1 STABLE DESLORATADINE COMPOSITIONS HRH2, SI, CMA1 PTAFR 3054/4885HRH1 11/4885FNTA 2551/4885
US-20100021542-A1 EXTENDED RELEASE ORAL DOSAGE COMPOSITION HRH2, QDPR, HRH1 PTAFR 1672/4885HRH1 3/4885FNTA 4107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.